Characteristics of ‘sawtooth shunt’ following anti-vascular endothelial growth factor for aggressive posterior retinopathy of prematurity
- 16 Downloads
To explore the characteristics of ‘sawtooth shunts (STS)’ following intravitreal anti-vascular endothelial growth factors (anti-VEGF) for aggressive posterior retinopathy of prematurity (AP-ROP).
Prospective observational study.
In a prospective observational study, 45 eyes of 24 babies receiving intravitreal anti-VEGF for AP-ROP or hybrid ROP were analyzed. Anti-VEGF molecule and doses: bevacizumab (0.62 mg or ½ IVB, n = 30 eyes; 0.25 mg or 1/5IVB, n = 9 eyes; 0.12 mg or 1/10 IVB, n = 1 eye); or ranibizumab (0.25 mg or ½IVR, n = 3 eyes; 0.1 mg or 1/5IVR, n = 2 eyes). They were followed every 1–2 week till disease regression with or without laser treatment. Development of STS, its variants, characteristics, timeline, and final outcomes was analyzed.
STS occurred in 26 (57.7%) eyes at 1–6 weeks following anti-VEGF injections and persisted for 1–14 weeks. While the shunt regressed spontaneously in half of the treated eyes (n = 13) with anti-VEGF alone, the other half (n = 13) required additional laser because of either non-compliance (n = 9) or recurrence (n = 4).
The STS was observed to be an important retinal vascular change seen in infants treated with intravitreal anti-VEGF at half adult doses. It warrants further studies to explore the association between STS and its association with disease recurrence or regression.
KeywordsRetinopathy of prematurity Aggressive posterior retinopathy of prematurity Intravitreal anti-vascular endothelial growth factors Retinal vascular changes Sawtooth shunt
All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Tapas Ranjan Padhi, Prabhjot Kaur, and Ashish Khalsa. The first draft of the manuscript was written by Tapas Ranjan Padhi, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
There is no direct support or grant related to this piece of work. However, the authors belong to an institute that receives support from Queen Elizabeth Diamond Jubilee Trust (UK), Miriam Hyman Memorial Trust (UK), Rastriya Bal Swasthya Karyakram (RBSK), and Dalmia holdings in India for its ongoing ROP work.
Compliance with ethical standards
Conflict of interest
The authors declare no conflicts of interest.
- 2.Katz X, Kychenthal A, Dorta P (2000) Zone I retinopathy of prematurity. JAAPOS 4:373–376Google Scholar
- 7.Wu L, Arevalo JF, Maia M et al (2009) Comparing outcomes in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration treated with two different doses of primary intravitreal bevacizumab: results of the Pan-American Collaborative Retina Study Group (PACORES) at the 12-month follow-up. Jpn J Ophthalmol 53(2):125–130CrossRefGoogle Scholar
- 14.Morizane H (1976) Initial sign and clinical course of the most severe form of acute proliferative retrolental fibroplasias (type II) [in Japanese]. Nippon GankaGakkaiZasshi 80:54–61Google Scholar
- 16.Harper CA III, Wright LM, Young RC et al (2017) Fluorescein angiographic evaluation of peripheral retinal vasculature after primary intravitreal ranibizumab for retinopathy of prematurity. Retina 39:1–6Google Scholar
- 19.Lorenz B, Stieger K, Jager M et al (2017) on behalf of the Giessen Cooperative ROP study group. Retinal vascular development with 0.312 mg intravitreal bevacizumab to treat severe posterior Retinopathy of Prematurity a longitudinal fluorescein angiographic study. Retina 37:97–111CrossRefGoogle Scholar
- 20.Tahija SG, Hersetyati R, Lam GC et al (2014) Fluorescein angiographic observations of peripheral retinal vessel outgrowth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity. Br J Ophthalmol 98:507–512CrossRefGoogle Scholar
- 21.Henaine-Berra A, Garcia-Aguirre G, Quiroz-Mercado H et al (2014) Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy. JAAPOS 18:120–123Google Scholar
- 22.Perente I, Eris E, Seymen Z, Cevik SG, Bekmez S (2019) Aggressive posterior retinopathy of prematurity treated with intravitreal bevacizumab: late period fluorescein angiographic findings. Graefes Arch Clin Exp Ophthalmol 257(6):1141–1146. https://doi.org/10.1007/s00417-019-04292-4 CrossRefPubMedGoogle Scholar